Eisai's Belviq does not increase MACE in CVOT for weight management drug

Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial (CVOT) of the chronic weight management drug.

Belviq was non-inferior, but not superior, to placebo on the primary efficacy endpoint of reducing the incidence of MACE plus hospitalization due to unstable angina, heart failure or any coronary revascularization...